Illumina (NASDAQ:ILMN) Given New $300.00 Price Target at Royal Bank of Canada

Illumina (NASDAQ:ILMN – Get Rating) had its price target decreased by Royal Bank of Canada from $303.00 to $300.00 in a research report report published on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the life sciences company’s stock.

Several other equities analysts have also recently commented on the stock. Argus cut shares of Illumina from a buy rating to a hold rating in a research report on Wednesday, January 25th. They noted that the move was a valuation call. Piper Sandler reaffirmed an overweight rating and set a $290.00 price target on shares of Illumina in a research report on Wednesday, February 8th. JPMorgan Chase & Co. dropped their price objective on shares of Illumina from $300.00 to $271.00 and set a neutral rating on the stock in a research note on Wednesday, February 8th. Citigroup lowered shares of Illumina from a neutral rating to a sell rating and dropped their price objective for the stock from $200.00 to $180.00 in a research note on Monday, December 12th. Finally, Cowen dropped their price objective on shares of Illumina from $350.00 to $296.00 in a research note on Tuesday, January 10th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Illumina currently has an average rating of Hold and a consensus price target of $249.40.

Illumina Stock Down 0.2 %

Shares of Illumina stock opened at $224.55 on Wednesday. The business has a 50-day moving average of $208.86 and a 200-day moving average of $208.73. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.28 and a quick ratio of 1.08. The company has a market capitalization of $35.48 billion, a PE ratio of -8.02, a P/E/G ratio of 8.32 and a beta of 1.15. Illumina has a 1-year low of $173.45 and a 1-year high of $371.16.

Illumina (NASDAQ:ILMN – Get Rating) last issued its quarterly earnings results on Tuesday, February 7th. The life sciences company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.11). Illumina had a positive return on equity of 3.79% and a negative net margin of 96.12%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the business posted $0.75 EPS. The business’s revenue for the quarter was down 9.2% on a year-over-year basis. As a group, equities analysts forecast that Illumina will post 1.41 EPS for the current fiscal year.

Insider Buying and Selling

In other Illumina news, SVP Susan H. Tousi sold 500 shares of the firm’s stock in a transaction dated Friday, January 6th. The stock was sold at an average price of $204.58, for a total transaction of $102,290.00. Following the completion of the sale, the senior vice president now directly owns 38,662 shares in the company, valued at approximately $7,909,471.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Illumina news, SVP Alexander Aravanis sold 5,398 shares of the firm’s stock in a transaction dated Wednesday, February 22nd. The stock was sold at an average price of $201.74, for a total transaction of $1,088,992.52. Following the completion of the sale, the senior vice president now directly owns 2,922 shares in the company, valued at approximately $589,484.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Susan H. Tousi sold 500 shares of the firm’s stock in a transaction dated Friday, January 6th. The stock was sold at an average price of $204.58, for a total value of $102,290.00. Following the sale, the senior vice president now owns 38,662 shares of the company’s stock, valued at $7,909,471.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,186 shares of company stock valued at $2,255,837. 0.13% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Illumina

Institutional investors have recently bought and sold shares of the business. Private Trust Co. NA acquired a new stake in Illumina during the 2nd quarter worth about $25,000. Elequin Securities LLC purchased a new stake in shares of Illumina during the 4th quarter worth about $29,000. Zions Bancorporation N.A. raised its stake in shares of Illumina by 97.6% during the 3rd quarter. Zions Bancorporation N.A. now owns 164 shares of the life sciences company’s stock worth $31,000 after purchasing an additional 81 shares in the last quarter. Guardian Wealth Advisors LLC purchased a new stake in shares of Illumina during the 3rd quarter worth about $33,000. Finally, Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 50.0% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 183 shares of the life sciences company’s stock worth $35,000 after purchasing an additional 61 shares in the last quarter. 87.97% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

(Get Rating)

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.